MPM BioImpact’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
Other funds holding TRDA
BBA
MPM BioImpact's TRDA Position: Q3 2026 in Review
MPM BioImpact sold out of Entrada Therapeutics (TRDA) in Q3 2026, closing a stake of 1,253,053 shares — an estimated $9.22M sold.
MPM BioImpact first reported a position in TRDA in Q2 2026 and held it in 1 quarter. The position peaked at $9.22M in Q2 2026. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.
- MPM BioImpact reported no remaining Entrada Therapeutics position as of Q3 2026 after selling out during the quarter.
- MPM BioImpact sold 1,253,053 Entrada Therapeutics shares in Q3 2026, an estimated $9.22M.
- MPM BioImpact first reported a position in Entrada Therapeutics in Q2 2026 and held it in 1 quarter.
- MPM BioImpact's Entrada Therapeutics position peaked at $9.22M in Q2 2026.
- 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.
Based on MPM BioImpact's 13F filing for Q3 2026, filed 16 Nov 2026.